Lyon – February 18th, 2026
With this agreement, Edelris will activate its proprietary, diverse, and lead-like 2Mio compound collection coupled with mass spectrometry-based screening technologies and its creative and dedicated teams of expert research scientists.
More news
About Edelris
Expanding the boundaries for your small molecule drug discovery!
Edelris is a leading Drug Discovery CRO, providing Compound Libraries, Organic & Medicinal Chemistry, High Throughput Screening, and Analytical expert services to the Pharmaceutical, Cosmetic, Crop Protection, and Biotech sectors.
Cross-fertilizing our combined experiences, knowledge, and techniques, together we break through to successful solutions for you.

